Isolation,Identification and Antimicrobial Activity Determination of Actinobacteria from the Lakes in Tibet

doi:10.13560/j.cnki.biotech.bull.1985.2019-0970

Abstract

Abstract: To study the diversity and antimicrobial activity of actinobacteria isolated from the sediment samples of lakes in Tibet aims to discover the medical actinobacteria producing novel active materials. Seven sediment samples were collected from lakes in Tibet,and from which actinobacteria were isolated using dilution plating method with 4 different media and then identified by 16S rRNA sequence analysis. Antimicrobial in vitro activities of the isolates were tested by paper disk diffusion method. In vivo activities of the isolates were evaluated for their ability to rescue Caenorhabditis elegans infected with tested pathogens. Results showed that the 73 actinobacteria were distributed in 8 genera affiliated with 5 families of 4 orders,Streptomyces and Micromonospora of them were the dominant genera. The 55 of 73 strains demonstrated positive results in antimicrobial assay,and the positive rate was 75.3%. Eight isolates presented fine antibacterial activity in vivo based on C. elegans infected with pathogens. Strain PF188 showed favorable antimicrobial activity both in vivo and in vitro,and deserved further research. The 16S rRNA sequence similarity between strain PF188 and the nearest Nonomuraea guangzhouensis NEAU-ZJ3^T was 98.13%,indicating that strain PF188 is a potential new species of Nonomuraea. The sediment samples from lakes in Tibet are rich in cultivable actinobacteria,which could be a potential source for the discovery of new antibiotics.

Key words: Tibet, lake actinobacteria, isolation, antimicrobial activities, Caenorhabditis elegans

PAN Wen-juan, LIN Jia-fu, WANG Xiao-tao, GUO Yi-dong, CHU Yi-wen, LIU Chao-lan. Isolation,Identification and Antimicrobial Activity Determination of Actinobacteria from the Lakes in Tibet[J]. Biotechnology Bulletin, 2020, 36(7): 97-103.

References

[1] Boucher HW, Talbot GH, Bradley JS, et al.Bad bugs, no drugs:no ESKAPE! an update from the infectious diseases society of america[J]. Clin Infect Dis, 2009, 48(1):1-12.
[2] Gilbert DN, Guidos RJ, et al.The 10 X’20 initiative:pursuing a global commitment to develop 10 new antibacterial drugs by 2020[J]. Clin Infect Dis, 2010, 50(8):1081-1083.
[3] 刘志恒. 放线菌-微生物药物的重要资源[J]. 微生物学通报, 2005, 32(6):143-145.
[4] Goodfellow M, Williams ST.Ecology of actinomycetes[J]. Annu Rev Microbiol, 1983, 37:189-216.
[5] Katsifas EA, Giannoutsou EP, Karagouni AD.Diversity of streptomycetes among specific Greek terrestrial ecosystems[J]. Lett Appl Microbial, 1999, 29(1):48-51.
[6] Alvan G, Edlund C, Heddini A.The global need for effective antibiotics—A summary of plenary presentations[J]. Drug Resis Updat, 2011, 14:70-76.
[7] Zotchev SB.Marine actinomycetes as an emerging resource for the drug development pipelines[J]. J Biotechnol, 2012, 158:168-175.
[8] Lazzarini A, Cavaletti L, Toppo G, et al.Rare genera of actinomyc-etes as potential producers of new antibiotics[J]. Anton Leeuw, 2000, 78:399-405.
[9] Clardy J, Fischbach MA, Currie CR.The natural history of antibiotics[J]. Curr Biol, 2009, 19(11):R437-R441.
[10] Tortorella E, Tedesco P, Esposito FP, et al.Antibiotics from deep-sea microorganisms:current discoveries and perspectives[J]. Mar Drugs, 2018, 16(10):355.
[11] Qin S, Li WJ, Klenk HP, et al.Editorial:Actinobacteria in special and extreme habitats:Diversity, function roles and environmental adaptations, second edition[J]. Front Microbiol, 2019, 10:944.
[12] Carro L, Casteo JF, Razmilic V, et al.Uncovering the potential of novel micromonosporae isolated from an extreme hyper-arid Atacama Desert Soil[J]. Sci Rep, 2019, 9:4678.
[13] Shirling EB, Gottlieb D.Methods for characterization of Streptomyces species[J]. Int J Syst Bacteriol, 1966, 16(3):313-340.
[14] Singh LS, Sharma H, Talukdar NC.Production of potent antimicrobial agent by actinomycete, Streptomyces sannanensis strain SU118 isolated from phoomdi in Loktak Lake of Manipur, India[J]. BMC Microbiol, 2014, 14:278.
[15] 程丽娟, 薛泉宏, 米航线, 等. 微生物学实验技术[M]. 西安:世界图书出版公司, 1988.
[16] Kirienko NV, Cezairliyan BO, Ausubel FM, et al.Pseudomonas aeruginosa PA14 Pathogenesis in Caenorhabditis elegans[J]. Methods Mol Biol, 2014, 1149:653-669.
[17] Tamura K, Stecher G, Peterson D, et al.MEGA6:molecular evolutionary genetics analysis version 6. 0[J]. Mol Biol Evol, 2013, 30(12):2725-2729.
[18] Brenner S.The genetics of Caenorhabditis elegans[J]. Genetics, 1974, 77:71-94.
[19] Moy TI, Ball AR, Ausubel FM, et al.Identification of novel antimicrobials using a live-animal infection model[J]. Proc Natl Acad Sci USA, 2006, 103(27):10414-10419.
[20] Kim M, Oh HS, Park SC, et al.Towards a taxonomic coherence between average nucleotide identity and 16S rRNA gene sequence similarity for species demarcation of prokaryotes[J]. Int J Syst Evol Micr, 2014, 64(2):346-351.
[21] 罗红丽, 黄英, 王黎明, 等. 西藏地区土壤放线菌种群多样性及拮抗活性研究[J]. 微生物学报, 2005(5):724-727.
[22] 夏占峰, 关统伟, 阮继生, 等. 艾丁湖沉积物放线菌多样性[J]. 微生物学报, 2011, 51(8):1023-1031.
[23] 张学武. 小单孢菌属的分类及应用研究[J]. 微生物学通报, 2006, 33(5):117-121.
[24] Zothanpuia, Passari AK, Leo VV, et al. Bioprospection of actinobacteria derived from freshwater sediments for their potential to produce antimicrobial compounds[J]. Microb Cell Fact, 2018, 17(1):68.
[25] Kumar RR, et al.Isolation of actinomycetes:A complete approach[J]. Int J Curr Microbiol Appl Sci, 2016, 5(5):606-618.
[26] 杨再昌, 杨小生. 秀丽隐杆线虫(Caenorhabditis elegans)在药物筛选中的应用[J]. 生命科学, 2009, 21(4):593-598.
[27] Breger J, Fuchs BB, Aperis G, et al.Antifungal chemical compounds identified using a C. elegans pathogenicity assay[J]. PLoS Pathog, 2007, 3(2):e18.
[28] 史秋佳, 杨剑萍, 陈缵光. 秀丽隐杆线虫作为抗感染药物筛选模型的研究进展[J]. 中国药理学通报, 2013, 29(10):1333-1336.
[29] Balla KM, Troemel ER.Caenorhabditis elegans as a model for intracellular pathogen infection[J]. Cell Microbiol, 2013, 15(8):1313-1322.